Open Access
Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE
Marc Humbert,Richard Beasley,J. Ayres +2 more
- pp 425-434
About:
The article was published on 2017-01-01 and is currently open access. It has received 848 citations till now. The article focuses on the topics: Omalizumab.read more
Citations
More filters
Les cellules dendritiques dans l'asthme et la rhinite allergique
Antoine Froidure,Charles Pilette +1 more
Farmacoeconomía de omalizumab
TL;DR: The authors revisar las publicaciones mas recientes y relevantes, including the guia NICE inglesa, that justifican and avalan el uso del farmaco, basandonos en criterios de farmacoeconomia aplicada.
Tratamiento del asma persistente y de difícil control: actualización de la terapia anti IgE Treatment of persistent and difficult-to-control asthma: updating of anti IgE therapy
TL;DR: Asma is un enfermedad inflamatoria cronica of las vias aereas en la que intervienen diferentes elementos celulares as mentioned in this paper.
Journal ArticleDOI
Clinical Outcomes of Omalizumab as Add-on Therapy for Severe Asthma Patients
TL;DR: Omalizumab showed great outcomes for its utilization in patients with serious hypersensitive asthma, and aided in progress of lung capacities, asthma control, asthma seriousness, and decrease of asthma intensifications, medical clinic affirmations, ICU confirmations and recurrence of oral steroid organization following a half year of omalizuab organizations.
References
More filters
Journal ArticleDOI
Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials.
Elizabeth F. Juniper,Gordon H. Guyatt,Robert S. Epstein,Penelope J. Ferrie,Roman Jaeschke,T K Hiller +5 more
TL;DR: A questionnaire suitable for all adults with asthma and designed to be responsive to within subject change and therefore may be used as a measure of outcome in clinical trials in asthma is developed.
Allergy, rhinitis, other respiratory diseases Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma
William W. Busse,Jonathan Corren,Bobby Q. Lanier,Margaret McAlary,Angel FowlerTaylor,Giovanni Della Cioppa,Niroo Gupta,Fort Worth +7 more
TL;DR: Omalizumab as discussed by the authors is a recombinant humanized anti-IgE mAb, which forms complexes with free IgE, blocking its interaction with mast cells and basophils.
Journal ArticleDOI
Proceedings of the ATS Workshop on Refractory Asthma Current Understanding, Recommendations, and Unanswered Questions
Sally E. Wenzel,John V. Fahy,Charles G. Irvin,Stephen P. Peters,Sheldon L. Spector,Stanley J. Szefler,Thomas B. Casale,Michelle M. Cloutier,Jack A. Elias,Mark C. Liu,Virginia Taggert +10 more
TL;DR: The proceedings of an American Thoracic Society (ATS)-sponsored workshop are hoped to serve as an aid to begin to define, understand, and manage these refractory patients.
Journal ArticleDOI
The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics
Markus Solèr,J. Matz,Robert G. Townley,R. Buhl,J. O'Brien,Howard Fox,J. Thirlwell,N. Gupta,G. Della Cioppa +8 more
TL;DR: Results indicate that omalizumab therapy safely improves asthma control in allergic asthmatics who remain symptomatic despite regular use of inhaled corticosteroids and simultaneous reduction in Corticosteroid requirement.